Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 2
2006 4
2007 3
2008 1
2009 3
2010 1
2012 2
2013 5
2014 7
2015 15
2016 11
2017 8
2018 25
2019 26
2020 21
2021 40
2022 52
2023 34
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bixiangzhang (65 results)?
TRIM proteins in hepatocellular carcinoma.
Lu K, Pan Y, Huang Z, Liang H, Ding ZY, Zhang B. Lu K, et al. Among authors: zhang b. J Biomed Sci. 2022 Sep 13;29(1):69. doi: 10.1186/s12929-022-00854-7. J Biomed Sci. 2022. PMID: 36100865 Free PMC article. Review.
DDX3X: structure, physiologic functions and cancer.
Mo J, Liang H, Su C, Li P, Chen J, Zhang B. Mo J, et al. Among authors: zhang b. Mol Cancer. 2021 Feb 24;20(1):38. doi: 10.1186/s12943-021-01325-7. Mol Cancer. 2021. PMID: 33627125 Free PMC article. Review.
The role of RNA m5C modification in cancer metastasis.
Zhang Q, Liu F, Chen W, Miao H, Liang H, Liao Z, Zhang Z, Zhang B. Zhang Q, et al. Among authors: zhang b. Int J Biol Sci. 2021 Aug 2;17(13):3369-3380. doi: 10.7150/ijbs.61439. eCollection 2021. Int J Biol Sci. 2021. PMID: 34512153 Free PMC article. Review.
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu XD, Bai D, Chen Y, Chen Y, Dai C, Guo R, Guo W, Hao C, Huang T, Huang Z, Li D, Li G, Li T, Li X, Li G, Liang X, Liu J, Liu F, Lu S, Lu Z, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan C, Wang G, Wang L, Wang S, Wen T, Xing B, Xiang B, Yan S, Yang D, Yin G, Yin T, Yin Z, Yu Z, Zhang B, Zhang J, Zhang S, Zhang T, Zhang Y, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Z, Qin S, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng S, Fan J; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Sun HC, et al. Among authors: zhang b. Hepatobiliary Surg Nutr. 2022 Apr;11(2):227-252. doi: 10.21037/hbsn-21-328. Hepatobiliary Surg Nutr. 2022. PMID: 35464283 Free PMC article. Review.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Among authors: zhang b. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.
Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression.
Liu F, Liao Z, Qin L, Zhang Z, Zhang Q, Han S, Zeng W, Zhang H, Liu Y, Song J, Chen W, Zhu H, Liang H, Chen X, Zhang B, Zhang Z. Liu F, et al. Among authors: zhang b. Hepatology. 2023 Nov 1;78(5):1384-1401. doi: 10.1097/HEP.0000000000000268. Epub 2023 Jan 13. Hepatology. 2023. PMID: 36631007 Free PMC article.
253 results